Business Wire

Heathrow selects Smiths Detection for its next generation cabin baggage and security screening equipment

Share

Smiths Detection, a global leader in threat detection and security screening technologies, today announces that it has been chosen to supply integrated checkpoints throughout Heathrow Airport, featuring the HI-SCAN 6040 CTiX computed tomography X-rays, to deliver an advanced level of security and efficiency.

The ECAC EDS CB C3 approved CT systems will see Heathrow meet the highest regulatory requirements, while helping the leading airport achieve its vision for the future of the security checkpoint for passengers and colleagues. The integrated checkpoints feature iLane automatic tray return systems and Checkpoint.Evoplus,Smiths Detection’s checkpoint operation management solution. The award also includes a 10-year equipment service agreement.

“We are delighted to once again be given the opportunity to work closely with Heathrow Airport to provide leading-edge technologies that bring the best security outcomes and passenger experience,” said Smiths Detection President, Roland Carter. “Both Smiths Detection and Heathrow are focused on intelligent solutions that deliver efficiency, security and resilience; and these new lanes will allow for improvements to be easily integrated as technology develops.”

As part of its decision making, Heathrow sought a supplier that could deliver a large scale, innovative, end-to-end solution and integrate the lanes into the airports’ existing operational environment with no impact to capacity or passenger experience.

Each piece of the integrated checkpoint uses Smiths Detection’s leading-edge technology designed to help increase security, improve passenger experience, and enhance operational efficiency:

  • HI-SCAN 6040 CTiX – This CT technology cabin baggage screening system provides the highest level of detection using 3D images with low false alarm rates. It delivers advanced explosives detection and can allow for electronics and liquids to remain in bags, helping to expedite the screening process.
  • Checkpoint.Evoplus fully integrates the checkpoint by combining individual components of the lane onto a single, intelligent operational management solution. It enables centralised screening by delivering scanned images to operators based at separate locations, resulting in optimised resources management and reduced operational costs.
  • iLane - a family of automatic tray return systems that use a modular smart lane design. By delivering a steady flow of trays, iLanes help remove bottlenecks and streamline the screening process to deliver higher throughput. The family includes iLane Selfcair, iLane.evo, and iLane.pro.

This contract is part of a long-term relationship between Heathrow and Smiths Detection, which includes the supply of industry leading hold baggage CT solutions.

The first lanes will be installed in anticipation of a recovery in passenger numbers later this year.

###

About Smiths Detection

Smiths Detection is a global leader in threat detection and screening technologies for aviation, ports and borders, urban security and defence. With more than 40 years of field-tested experience, we deliver the solutions needed to protect society from the threat and illegal passage of explosives, prohibited weapons, contraband, toxic chemicals and narcotics.

Our mission is to help make the world a safer place – we do this by using technology to develop innovative solutions and services which protect life, safeguard society and uphold the free flow of trade.

For more information on Smiths Detection’s solutions and services, visit https://www.smithsdetection.com/

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Contacts
Tom Hufton / Georgina Reeves
FTI Consulting
sc.smithsdetection@fticonsulting.com
+44 (0)20 3727 1000

Sophie Mills
Global Communications Manager
Sophie.mills@smithsdetection.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Newmont Publishes 2023 Sustainability Report and 2023 Tax & Royalties Report18.4.2024 14:00:00 CEST | Press release

Newmont Corporation (NYSE: NEM, TSX: NGT, ASX: NEM, PNGX: NEM) today published its 2023 Sustainability Report and its 2023 Taxes and Royalties Contributions Report. The reports highlight the company’s material ESG and socio-economic contributions over the past year. This year marks the 20th anniversary for Newmont’s Annual Sustainability Report, representing a milestone for the company as a longstanding industry leader in sustainability. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417961090/en/ Newmont's 2023 Sustainability Report (Graphic: Business Wire) "Our 2023 Sustainability Report demonstrates our unwavering commitment to responsible resource management and the integral role that Newmont plays in creating a more sustainable future," said Newmont Chief Safety and Sustainability Officer Suzy Retallack. "We recognize the responsibility we have to mitigate our environmental impact and make a difference in the areas w

Vertex Announces Advancements of Suzetrigine (VX-548) in Acute and Neuropathic Pain18.4.2024 14:00:00 CEST | Press release

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced important advancements across its suzetrigine pain program, which has the potential to be the first new class of medicine for acute and neuropathic pain in more than two decades. Suzetrigine is an oral selective NaV1.8 pain signal inhibitor (formerly known as VX-548). Following the positive Phase 3 results in acute pain announced in January 2024, the Food and Drug Administration (FDA) has granted a rolling New Drug Application (NDA) submission for suzetrigine in moderate-to-severe acute pain. Vertex has started the rolling submission process and is on track to complete the submission in the second quarter of 2024. Suzetrigine was previously granted FDA Fast Track and Breakthrough Therapy designations in moderate-to-severe acute pain. In neuropathic pain, Vertex released positive results from its Phase 2 study in December 2023 and recently completed a successful end-of-phase 2 meeting with the FDA. Vertex is now preparin

MediaCo Acquires Estrella Media’s Content and Digital Operations18.4.2024 13:36:00 CEST | Press release

MediaCo Holding Inc. (Nasdaq: MDIA) (“MediaCo”) today announced that it has acquired all of Estrella Media’s network, content, digital, and commercial operations. Among the Estrella Media brands joining MediaCo are the EstrellaTV network and its influential linear and digital video content business, and Estrella Media’s expansive digital channels, including its four FAST channels – EstrellaTV, Estrella News, Cine EstrellaTV, and Estrella Games – and the EstrellaTV app. The transaction closed on April 17, 2024. MediaCo, which operates marquee urban radio stations HOT 97 and WBLS 107.5 in New York City, will be adding Estrella Media’s Spanish-language video, audio, and digital content operations under the same umbrella. This transaction will also allow MediaCo to reach the established audiences of Estrella Media’s market-leading Regional Mexican radio stations, including Que Buena Los Angeles, home of the Don Cheto Al Aire nationally syndicated morning radio show, La Raza in Houston and

TriLink BioTechnologies ® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production18.4.2024 13:36:00 CEST | Press release

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility. The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities. The milestone opening is expected to help advance the field of mRNA-based medicine as developers flock to leverage the promising modality for a growing list of indications. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240418722567/en/ TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®) Located in the Sorrento Valley area of San Diego, the facility features individual Grade C cleanroom suites for mRNA manufacturing, i

Cushman & Wakefield Appointed by Standard Chartered Bank to Deliver Property Services across Asia and Global Asset and Transaction Management18.4.2024 13:00:00 CEST | Press release

Cushman & Wakefield (NYSE: CWK), a leading global real estate services firm, announces that it has been appointed by Standard Chartered Bank (the Bank) to provide services to support its Asia workplace transformation, and Global Asset and Transaction Management for the Bank’s 11m square foot global real estate portfolio. The five-year mandate will encompass global Asset & Transactions Management and Property Services across Asia, including Integrated Facilities Management, Project & Design Management Services, Space Planning, Occupancy Management, Health, Safety and Wellbeing and Physical Security and will take effect from 1 July 2024. In support of delivering a best-in-class corporate, investment, wealth and retail banking experience, Cushman & Wakefield will be key in accelerating the Bank’s client strategy across its physical and digital networks. In partnership with the Bank’s Wealth and Retail Banking (WRB), and Corporate & Investment Banking (CIB) arms, the mandate will look towa

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye